{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-010095","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.682265+00:00","generated_at":"2026-06-25T15:31:46.312839+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Terns Pharma Q1 net loss $13.8M; cash $151.3M; pipeline prioritization extends runway into 2025","bullets":["Net loss of $13.8M ($0.55 per share) vs $13.3M in Q1 2021; R&D $8.1M, G&A $5.7M.","Cash and equivalents $151.3M, expected to fund operations into 2025 with three clinical readouts.","IND opened for NASH Phase 2a trial of TERN-501 (mono + combo with TERN-101); top-line data expected H2 2023.","TERN-601 (oral GLP-1) IND-enabling underway; Phase 1 for obesity expected in 2023.","Partner Hansoh initiated Phase 1 trial of TERN-701 in CML in China; dosing underway."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-010095","json":"https://secwatch.observer/filing/0000950170-22-010095.json","markdown":"https://secwatch.observer/filing/0000950170-22-010095.md","text":"https://secwatch.observer/filing/0000950170-22-010095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000095017022010095/0000950170-22-010095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000095017022010095/tern-20220516.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T15:31:46.312839+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}